

Novugen Oncology (formerly known as Oncogen Pharma) & Brightgene Bio-Medical Technology Announce Strategic Partnership to Enter U.S.A Pharma Market

SHAH ALAM, MALAYSIA, June 14, 2021– Novugen Oncology Sdn Bhd (formerly known as Oncogen Pharma) a Malaysia-based generic pharmaceutical manufacturer and BrightGene Bio-Medical Technology Co., Ltd (Shanghai Stock Exchange Stock code: 688166) from China, have announced signing of an agreement to develop, manufacture, market, and distribute Generic products for the United States market. The initial partnership agreement signed between the two companies includes one complex generic product under Oncology segment, which has already completed the development process. Under the terms of this agreement, the expertise of each company will be leveraged to create a highly efficient and effective product flow, from active pharmaceutical ingredients (API) manufacturing through to regulatory approval and distribution, that will bring high quality generic drugs to the USA market over the next few years.

Rahil Mahmood, Chief Executive Officer of Novugen Oncology said, “We are pleased to announce our strategic partnership with BrightGene Bio-Medical Technology to accelerate the development and manufacturing of oncology product for patients in the U.S.A market. The combination of the two companies’ development and manufacturing capabilities represent yet another step in our unwavering commitment towards developing and providing access to high quality, affordable and innovative medications to patients in the U.S.A and to put Malaysia on the global map of innovative pharmaceutical development”.

The product selection committee, made up of 3 members from each company, has chosen the first product to build a balanced offering in the Oncology category, providing potential customers with a single source for the most important molecules of the category.

Novugen Oncology’s responsibilities within the partnership will include product development, filing the abbreviated new drug applications (ANDAs) for USFDA approval and commercial launch of the products in USA market. Manufacturing for these products will be carried out at its Oncology facility in Malaysia for export to the USA.

For additional group of products, Novugen Oncology and Brightgene have already begun to identify several more products to pursue in the complex generic category for various therapeutic areas. The two companies fully expect this agreement to expand significantly in the short term and for it to last for many years.

About Novugen

Novugen is a wholly owned subsidiary company of a UAE based group with more than 30 years of experience in strategic healthcare businesses and development of world class healthcare facilities around the globe. Novugen's globally minded strategy, synergistic approach and wealth of experience enable us to respond to the complex challenge of bringing hard-to-source and technology-intensive products to market while maintaining affordable pricing and rigorous quality assurance. As a technology leader, we create efficiency by integrating our total value chain. At Novugen, our science and business teams work together seamlessly to innovate new concepts and fresh ideas to accelerate the launch of pharmaceuticals that lack robust generic alternatives due to their complexity.

Website: www.novugen.com

Source:

https://www.einnews.com/pr_news/543758218/oncogen-pharma-malaysia-brightgene-bio-medical-technology-announce-strategic-partnership-to-enter-u-s-a-pharma-market